Level Four Advisory Services’s AbbVie ABBV Stock Holding History

Level Four Advisory Services’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500	Closed	-$1.88K	–	760
2023 Q2	$1.88K	Buy	+500	New	+$73.3K	﹤0.01%	800

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Level Four Advisory Services's ABBV Position: Q1 2026 in Review

Level Four Advisory Services increased its AbbVie (ABBV) stake by 0.37% in Q1 2026, buying an estimated $108K and bringing the position to 132,234 shares worth $28.8M. The position accounts for 0.94% of the portfolio, ranked #15.

Level Four Advisory Services first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. The position peaked at $35.4M in Q1 2023. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Level Four Advisory Services held 132,234 shares of AbbVie worth $28.8M as of Q1 2026.
Level Four Advisory Services bought 485 AbbVie shares in Q1 2026, an estimated $108K.
AbbVie made up 0.94% of Level Four Advisory Services's portfolio in Q1 2026, its #15 holding.
Level Four Advisory Services first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
Level Four Advisory Services's AbbVie position peaked at $35.4M in Q1 2023.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Level Four Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.